Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | May 22, 2019 | June 03, 2019 |
| Cellular Biomedicine Group, Inc.CBMG · Entity 142413 | Director | May 18, 2018 | May 22, 2018 |
| EXICURE, INC.XCUR · Entity 8068 | Director | June 02, 2021 | June 04, 2021 |
| Evolus, Inc.EOLS · Entity 5341 | Director | January 23, 2020 | January 25, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date May 22, 2019 · Filed June 03, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
This filing explicitly reported no securities owned.
Cellular Biomedicine Group, Inc.
Report date May 18, 2018 · Filed May 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy) (2014 Plan)SEC Table II · derivative / convertible security · Conversion / exercise price $19.71 · Expires 2028-05-18 | Direct | 4,784 |
Reported balance
After 2018-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-18 · Grant · Acquired 4,499 · Balance 4,784 F1: This option becomes exercisable and fully vests on April 26, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option becomes exercisable and fully vests on April 26, 2019.
EXICURE, INC.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2031-06-01 | Direct | 50,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.
Evolus, Inc.
Report date January 23, 2020 · Filed January 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.19 · Expires 2030-01-23 | Direct | 23,458 |
Reported balance
After 2020-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-23 · Grant · Acquired 23,458 · Balance 23,458 F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 4, 2021 21:15 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-21-038322 · doc4.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 23:20 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 21,693 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001209191-20-035122 · doc4.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,693 Underlying: Common Stock · 21,693 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 02:08 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001570562-20-000040 · wf-form4_157991810249418.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2030-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| August 02, 2019 Filed Aug 7, 2019 00:07 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantStock Option (right to buy) · Derivative | 43,386 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001698530-19-000118 · wf-form4_156513646290042.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,386 Underlying: Common Stock · 43,386 shares Expires 2029-08-01 F1 · derivative.exercise_date: (1) This option vests in 36 substantially equal monthly installments from August 2, 2019, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:19 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000021 · wf-form4_154846556396551.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:18 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock | 2,898 | $34.94 | $101,255.83 |
DisclosureSEC source: 0001570562-18-000053 · wf-form4_152848912138903.xml · nonDerivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,040 F1 · price: The shares were purchased in multiple trades at prices ranging from $34.8064 to $35.1064. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 21:08 UTC | Evolus, Inc. EOLS · Entity 5341 | PurchaseCommon Stock | 7,142 | $29.19 | $208,471.41 |
DisclosureSEC source: 0001570562-18-000051 · wf-form4_152823283258474.xml · nonDerivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,142 F1 · price: The shares were purchased in multiple trades at prices ranging from $28.93 to $29.3899. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 18, 2018 Filed May 22, 2018 16:10 UTC | Cellular Biomedicine Group, Inc. CBMG · Entity 142413 | GrantNon-Qualified Stock Option (right to buy) (2014 Plan) · Derivative | 4,499 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001654954-18-005777 · section16.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,784 Underlying: Common Stock · 4,499 shares Expires 2028-05-18 F1 · derivative.exercise_date: This option becomes exercisable and fully vests on April 26, 2019. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 17:37 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001570562-18-000022 · wf-form4_152476420693760.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2028-04-24 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 6, 2018. Read SEC document |
| February 06, 2018 Filed Mar 13, 2018 12:40 UTC | Cellular Biomedicine Group, Inc. CBMG · Entity 142413 | GrantNon-Qualified Stock Option (right to buy) (2014 Plan) · Derivative | 285 | $0.00 Strike: $19.35 | $0.00 |
DisclosureSEC source: 0001654954-18-002443 · section16.xml · derivative · entry 1 Hau Bosun · CIK 0001730224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285 Underlying: Common Stock · 285 shares Expires 2028-02-06 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.